MESO

Remestemcel-L (mesenchymal stem cells)

COVID

Stage (next event)

Expected Date

Phase 3 (Final Interim Analysis)

December 2020 (Est)

Catalyst Info & Data Links

TITLE: Remestemcel-L (mesenchymal stem cells) in COVID - Phase 3 (Final Interim Analysis) 

  • ClinicalTrial.gov (NCT04371393): MSCs in COVID-19 ARDS


WHAT IS THE CATALYST EVENT?


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • December 2020


PRIOR DATA/EVENTS

PRESS RELEASES

Mechanism of Action

MECHANISM OF ACTION / RATIONALE

  • The proposed mechanism of action for remestemcel-L is a reduction in pathogenic inflammation mediated through the immunomodulatory activity of the MSC active ingredient. Given this mode of action, controlling the immunomodulatory bioactivity is critical to maintaining consistent product quality.

Updated by HC

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

ASCO 2018 Amp Noteworthy Abstracts

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon